Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray
暂无分享,去创建一个
K. Aldape | Yun Wu | A. Sahin | R. Broaddus | M. Routbort | K. Patel | L. Medeiros | Hui Yao | C. Albarracin | L. Huo | R. Luthra | Hui Chen | S. Roy-Chowdhuri | Xinyan Lu | Rajesh R. Singh | B. Mishra | M. Mehrotra | Shumaila Virani | R. K. Shamanna | R. Abraham | A. Bousamra
[1] P. Campbell,et al. Genomic Characterization of Primary Invasive Lobular Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Routbort,et al. Comprehensive Screening of Gene Copy Number Aberrations in Formalin-Fixed, Paraffin-Embedded Solid Tumors Using Molecular Inversion Probe-Based Single-Nucleotide Polymorphism Array. , 2016, The Journal of molecular diagnostics : JMD.
[3] L. Varanasi,et al. Frequency of chromosome 17 polysomy in relation to CEP17 copy number in a large breast cancer cohort , 2016, Genes, chromosomes & cancer.
[4] Jeffrey H. Chuang,et al. The tandem duplicator phenotype as a distinct genomic configuration in cancer , 2016, Proceedings of the National Academy of Sciences.
[5] A. Bousamra. Molecular Inversion Probe Technology Generates High-Quality HER2 Copy Number Data in Formalin-Fixed Paraffin-Embedded Breast Cancer Tissue , 2016 .
[6] G. Tse,et al. FGFR1 is an adverse outcome indicator for luminal A breast cancers , 2015, Oncotarget.
[7] Cheng-Zhong Zhang,et al. Chromothripsis: A New Mechanism for Rapid Karyotype Evolution. , 2015, Annual review of genetics.
[8] L. Saal,et al. Remarkable similarities of chromosomal rearrangements between primary human breast cancers and matched distant metastases as revealed by whole-genome sequencing , 2015, Oncotarget.
[9] Razelle Kurzrock,et al. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing , 2015, Clinical Cancer Research.
[10] Sarah H. Johnson,et al. Chromosomal catastrophe is a frequent event in clinically insignificant prostate cancer , 2015, Oncotarget.
[11] Donavan T. Cheng,et al. Consistent copy number changes and recurrent PRKAR1A mutations distinguish Melanotic Schwannomas from Melanomas: SNP‐array and next generation sequencing analysis , 2015, Genes, chromosomes & cancer.
[12] P. Tan,et al. Expression of FGFR1 is an independent prognostic factor in triple-negative breast cancer , 2015, Breast Cancer Research and Treatment.
[13] Phil Quirke,et al. Cross-laboratory validation of the OncoScan® FFPE Assay, a multiplex tool for whole genome tumour profiling , 2015, BMC Medical Genomics.
[14] M. Raffeld,et al. Chromothriptic Cure of WHIM Syndrome , 2015, Cell.
[15] Jong-Hyeon Jeong,et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] K. Aldape,et al. Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours , 2014, British Journal of Cancer.
[17] G. Babiera,et al. Molecular cytogenetic characterization of mammary neuroendocrine carcinoma. , 2014, Human pathology.
[18] C. Greenwood,et al. Chromosome-breakage genomic instability and chromothripsis in breast cancer , 2014, BMC Genomics.
[19] J. Baselga,et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. , 2014, The Lancet. Oncology.
[20] John M S Bartlett,et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.
[21] Jan Koster,et al. Prevalence and clinical implications of chromothripsis in cancer genomes , 2014, Current opinion in oncology.
[22] Alex M. Fichtenholtz,et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.
[23] Li Ding,et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. , 2013, Cell reports.
[24] Rashmi Kanagal-Shamanna,et al. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. , 2013, The Journal of molecular diagnostics : JMD.
[25] J. Korbel,et al. Criteria for Inference of Chromothripsis in Cancer Genomes , 2013, Cell.
[26] Mark D. Johnson,et al. Functional genomic analysis of chromosomal aberrations in a compendium of 8000 cancer genomes , 2013, Genome research.
[27] D. Zwijnenburg,et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes , 2012, Nature.
[28] L. Goldstein,et al. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] N. Carter,et al. Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development , 2011, Cell.
[30] Anthony Rhodes,et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] A. Børresen-Dale,et al. COMPLEX LANDSCAPES OF SOMATIC REARRANGEMENT IN HUMAN BREAST CANCER GENOMES , 2009, Nature.
[32] A. Ashworth,et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray‐based CGH analysis , 2009, The Journal of pathology.
[33] S. Gunn,et al. Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event , 2009, Modern Pathology.
[34] P. Spellman,et al. High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays , 2009, BMC Medical Genomics.
[35] S. Tavaré,et al. High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer , 2007, Genome Biology.
[36] Des Powe,et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis , 2007, Breast Cancer Research.
[37] Kenny Q. Ye,et al. Novel patterns of genome rearrangement and their association with survival in breast cancer. , 2006, Genome research.
[38] D. Berry,et al. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[40] C. Osborne,et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[42] N. Robert,et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] D. Birnbaum,et al. Expression of the FGFR1 gene in human breast‐carcinoma cells , 1994, International journal of cancer.
[44] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.